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Abstract
Background:  Several  studies  have  demonstrated  that  medication  is  commonly  used  off-label
in children  with  allergic  diseases.  The  aim  of  this  study  was  to  characterise  off-label  use  of
prescriptions  for  allergic  diseases  in  pre-school  children  from  an  allergology  outpatient  unit.
Methods: The  clinical  files  of  children  aged  ≤6  years  seen  in  a  reference  allergology  consultation
with asthma,  allergic  rhinitis,  and/or  atopic  eczema  were  reviewed.  A  total  of  500  patients  were
consecutively  observed  from  January  to  June  2012.  The  data  collected  included  gender,  age,
diagnosis,  and  prescriptions  with  the  respective  daily  dosage.
Results:  A  total  of  1224  prescriptions  were  registered.  The  most  prescribed  medications  were
oral antihistamines  (34.6%),  antileukotrienes  (22.6%),  topical  nasal  corticosteroids  (20.3%),  and
inhaled corticosteroids  (17.7%).  From  all  prescriptions,  422  (34.5%)  were  considered  off-label
for age  (62.6%),  dosage  (31.7%),  or  clinical  indication  (5.7%).  Off-label  use  was  more  frequent
in children  aged  <2  years,  with  73.5%  prescribed  for  children  of  this  age.
Conclusions:  Off-label  use  of  drugs  for  the  treatment  of  paediatric  allergic  diseases  is  high.
However, these  prescriptions  are  not  necessarily  wrong,  and  are  recommended  in  many  guide-
lines. Randomised  controlled  studies  are  limited  by  methodological  difficulties  creating  the
need for  more  observational  studies  in  order  to  further  evaluate  the  safety  and  efficacy  of
drugs used  in  children.
© 2012  SEICAP.  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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Many  drugs  used  in  the  treatment  of  allergic  diseases  are
not  appropriately  studied  in  the  paediatric  population,  espe-
cially  in  infants  and  younger  children.  Nonetheless,  their
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http://dx.doi.org/10.1016/j.aller.2013.02.011ff-label  use,  i.e.  use  outside  the  formal  indications  autho-
ised  by  the  regulatory  authorities,  in  a  different  age  group,
ose,  or  indication1 is  common  in  many  paediatric  illnesses
ike  allergic  disease.  This  happens  because  of  practical  and
thical  considerations  in  carrying  out  clinical  trials  in  this
opulation.2 In  general,  off-label  prescription  rates  rangeJ.  Off-label  prescribing  for  allergic  diseases  in  pre-school
rg/10.1016/j.aller.2013.02.011
rom  11%  to  37%  in  children  treated  in  the  community
etting,  and  in  up  to  62%  of  children  in  paediatric  hospi-
al  wards.3 The  major  concern  with  this  off-label  use  is
he  increased  risk  of  adverse  drug  reactions.4 Additionally,
aña, S.L. All rights reserved.
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Table  1  Drugs  used  for  treatment  of  asthma,  allergic  rhinitis,  and  atopic  eczema,  and  their  authorizations  for  use  according
to age  and  dose.
Category  Drug  Minimum  age  Maximum  dose
IC Budesonide  2  years  400  g/day  --  2  to  7  years
Fluticasone  12  months 200  g/day  --  1  to  4  years;  400  g/day  --  4  to  16  years
NC Budesonide  6  years 400  g/day
Fluticasone  furoate 6  years 55  g/day
Mometasone  6  years 100  g/day
LABAa Salmeterol  4  years 100  g/day
AH Cetirizine  2  years  5  mg/day  --  2  to  6  years;  10  mg/day  --  6  to  18  years
Levocetirizine  2  years  2.5  mg/day  --  2  to  6  years;  5  mg/day  --  older  than  6  years
Loratadine 2  years  5  mg/day  --  2  to  6  years;  10  mg/day  --  6  to  18  years
Desloratadine  12  months  1.25  mg/day  --  1  to  5  years;  2.5  mg/day  --  6  to  12  years
Ebastine 2  years  2.5  mg/day  --  2  to  5  years;  5  mg/day  --  6  to  11  years
Ketotifen 6  months  0.1  mg/kg/day  -  6  months  to  3  years;  2  mg/day  --  older  than  3  years
AL Montelukast  6  months  4  mg/day  --  6  months  to  5  years;  5  mg/day  --  6  to  14  years
TI Pimecrolimus  2  years
Source:  Infarmed, I.P.11
IC: inhaled corticoids; NC: nasal topic corticoids; LABA: long acting 2 agonists; AH: oral antihistamines; AL: anti-leukotriene; TI: topic
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a Always used in combination with fluticasone -- authorisations i
ounger  children  and  infants  have  a  considerably  increased
isk  of  prescription  errors,  especially  dosage  errors.5
However,  off-label  prescriptions  are  not  necessarily
ncorrect,6 and  may  even  be  appropriate  in  certain  clini-
al  situations  provided  there  is  no  alternative  treatment,
nd  when  the  likely  benefits  outweigh  the  potential  risks,7
uch  as  when  conventional  treatments  are  unable  to  achieve
ontrol  of  the  disease.  The  potential  advantages  of  off-label
rescribing,  apart  from  the  probable  benefit  to  the  indi-
idual  patient,  are  that  new  therapeutic  uses  may  be
escribed,  and  data  on  the  efficacy  and  safety  of  the  drug
eing  used  in  new  settings  may  be  collected.8 With  off-
abel  prescriptions,  the  physician  must  act  as  an  enlightened
ntermediary.  On  the  one  hand,  managing  the  regulatory
ata  aimed  at  ensuring  the  effectiveness  and  safety  of  the
rescription,  and  on  the  other  hand,  putting  all  his  or  her
nowledge  into  serving  the  interests  of  the  patient.
Several  studies  have  consistently  shown  that  off-label
se  in  children  is  common.  A  population-based  cohort  study
arried  out  in  primary  care  units  in  Holland  assessed  the
rescribing  of  respiratory  drugs  in  2502  children,  showing
hat  almost  37%  were  off-label,  and  39%  in  this  group  were
rescriptions  for  asthma.9 The  TEDDY  study,  comparing  the
se  of  anti-asthmatic  drugs  in  children  in  Holland,  Italy,
nd  the  United  Kingdom,  established  that  off-label  use  of
2-agonists  and  inhaled  corticosteroids  is  frequent,  inclu-
ing  up  to  80%  of  the  inhaled  budesonide  prescriptions  in
taly.10
In  Portugal,  few  studies  exist  concerning  off-label  use
f  drugs  in  paediatric  populations,  and  none  are  speci-
cally  related  to  drugs  for  the  treatment  of  aller-Please  cite  this  article  in  press  as:  Morais-Almeida  M,  Cabral  A
children.  Allergol  Immunopathol  (Madr).  2013.  http://dx.doi.o
ic  disease.  This  study  aimed  to  characterise  off-label
rescribing  of  drugs  used  in  the  treatment  and  con-
rol  of  asthma,  allergic  rhinitis,  and  atopic  eczema  in  a
ignificant  sample  of  pre-school  aged  children  followed
A
a
a
scal to isolated use.
y  allergy  specialists  at  a reference  allergology  consulta-
ion.
ethods
he  clinical  files  of  children  aged  ≤6  years  followed  in  our
llergology  consultation  who  were  diagnosed  with  current
sthma,  allergic  rhinitis,  and/or  atopic  eczema  phenotypes,
ith  predominantly  moderate  to  severe  clinical  presenta-
ions,  were  systematically  reviewed.  Consecutive  medical
isits  were  analysed  from  the  beginning  of  January  2012  until
he  inclusion  of  a  total  of  500  patients  (June  2012).
The  data  collected  included  gender,  age,  diagnosis,  and
rugs  prescribed  for  the  control  of  allergic  diseases  that
ere  used  for  a  minimum  period  of  two  weeks,  as  well
s  the  respective  dosages.  Drugs  used  for  acute  treatment
ere  not  considered.  The  drugs  included  were  classified  as
ollows:  (1)  inhaled  corticosteroids  (IC);  (2)  nasal  topical
orticosteroids  (NC);  (3)  long  acting  2  agonists  (LABA);  (4)
ral  antihistamines  (AH);  (5)  oral  antileukotrienes  (AL);  (6)
opical  immunomodulators  (TI).
The  formal  indications  for  each  drug  were  available  from
nfarmed  --  Autoridade  Nacional  do  Medicamento  e  Pro-
utos,  I.P.  (Infarmed),11 the  national  authority  on  drug
ontrol  and  authorisation,  and  were  confirmed  by  the  phar-
aceutical  companies  responsible  for  their  production  and
istribution;  these  indications  were  systematically  com-
ared  by  the  authors,  who  found  no  discrepancies  (Table  1).
The  age  groups  were  classified  according  to  the  paedi-
tric  age  definitions  provided  by  the  European  MedicinesJ.  Off-label  prescribing  for  allergic  diseases  in  pre-school
rg/10.1016/j.aller.2013.02.011
gency  (EMA).12 As  such,  the  sample  was  divided  as  follows:
ge  <  2  years,  and  age  2--6  years.  Although  EMA  considers  an
ge  group  for  newborns  ‘‘younger  than  one  month  old’’,  the
ample  did  not  include  any  patients  in  this  age  group.
ARTICLE IN+ModelALLER-510; No. of Pages 6
Beyond  the  leaflet  
Table  2  Characterisation  of  the  study  population.
Total  (%)
Gender
Female  195  (61)
Male 305  (39)
Age
<2 years  80  (16)
2--6 years  420  (84)
Diagnosis
Asthma 238
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Atopic eczema  35
The  study  was  approved  by  the  ethical  committee  of  the
institution.
Statistical  analysis
Statistical  comparisons  (chi-square)  were  performed  using
the  statistical  program  IBM  SPSS  Statistics  version  19.0.0
(2010,  Chicago,  IL,  USA),  and  p  <  0.05  was  considered  sta-
tistically  significant.
ResultsPlease  cite  this  article  in  press  as:  Morais-Almeida  M,  Cabral  A
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A  total  of  500  patient  files  were  verified  (Table  2),
corresponding  to  1224  prescriptions  used  to  control
the  previously  mentioned  pathologies.  The  most  pre-
scribed  drugs  were  oral  antihistamines  (34.6%),  followed
d
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m
Table  3  Total  number  of  prescriptions  studied.
Category  Drug  
Total  
Total  
IC Budesonide  9  1  
Fluticasone 208  94  
NC Budesonide 11  9  
Fluticasone furoate  28  12  
Mometasone  209  168  
LABA Salmeterol  56  17  
AH Cetirizine 115  16  
Levocetirizine  209  52  
Loratadine 3  0  
Desloratadine  53  19  
Ebastine 5  5  
Ketotifen 38  1  
AL Montelukast  277  25  
TI Pimecrolimus  3  3  
Totals 1224  422  
Results in n, except when pointed out. IC: inhaled corticoids; NC: 
antihistamines; AL: anti-leukotriene; TI: topic immunomodulator. PRESS
3
y  antileukotrienes  (22.6%),  nasal  topical  corticosteroids
20.3%),  inhaled  corticosteroids  (17.7%),  association  of
nhaled  corticosteroids  and  LABA  (4.6%),  and,  finally,  topic
mmunomodulators  (0.2%).  The  most  often  used  drugs  were
ontelukast  (22.6%),  levocetirizine  (17.1%),  mometasone
17.1%),  and  fluticasone  (17.0%)  (Table  3).
Of  all  the  prescriptions,  802  (65.5%)  were  authorised  for
se  in  children  and  were  used  according  to  the  formally
pproved  indication.  The  remaining  422  (34.5%)  drugs  were
sed  off-label,  outside  the  approvals  for  age  (62.6%),  dosage
31.7%),  or  clinical  indication  (5.7%).  Mometasone,  flutica-
one,  and  levocetirizine  were  the  drugs  most  frequently
rescribed  in  this  fashion  (Table  3).  In  Portugal,  as  in  sev-
ral  other  European  countries,  mometasone  is  authorised
olely  for  children  aged  >6  years  and  is  therefore  frequently
sed  off-label.  The  same  occurs  with  levocetirizine,  which
s  authorised  only  for  children  aged  >2  years.  As  for  fluti-
asone,  its  off-label  use  was  related  to  prescribing  doses
reater  than  the  approved  dosage.  Only  montelukast  was
rescribed  outside  of  its  clinical  indication  since,  in  Portu-
al  as  in  other  countries,  it  can  only  be  used  as  adjunctive
herapy  in  the  preventive  treatment  of  asthma  in  children
ge  <2  years,  being  not  authorised  as  a  single  therapy,11 with
he  exception  if  it  is  not  possible  to  use  inhaled  steroids  as
ontroller  medication.
Dividing  the  prescriptions  into  categories,  we  highlight
he  off-label  use  of  nasal  topical  corticoids  in  over  75%  of  the
otal  prescription  (Table  4),  which  was  always  due  to  the  age
imitation.  We  also  note  the  off-label  use  of  pimecrolimusJ.  Off-label  prescribing  for  allergic  diseases  in  pre-school
rg/10.1016/j.aller.2013.02.011
ue  to  age  in  cases  of  severe  atopic  eczema,  despite  its
educed  prescribing  in  three  patients  aged  8,  10,  and  12
onths,  respectively.
Prescriptions
Off-label
%  Age  Dose  Indication
11.1  1  --  --
45.2  --  94  --
81.8  9  --  --
42.9  12  --  --
80.4  168  --  --
30.4  17  --  --
13.9  6  10  --
24.9  48  4  --
0  --  --  --
35.8  --  19  --
100.0  --  5  --
2.6  --  1  --
9.0  --  1  24
100.0  3  --  --
34.5  264  (62.6%)  134  (31.7%)  24  (5.7%)
nasal topic corticoids; LABA: long acting 2 agonist; AH: oral
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Table  4  Prescriptions  according  to  age  and  drug  category.
Total  Authorised  Off-label
Total  %  Total  %  Age  Dose  Indication
Age  group  (years)
<2  181  48  26.5  133  73.5* 68  41  24
2--6 1043  754  72.5  289  27.5* 195  94  --
Drug category
IC  217  122  56.2  95  43.8  1  94  --
NC 248  59  23.8  189  76.2  189  --  --
IC +  LABA 56  39  69.6  17  30.4  17  --  --
AH 423  330  78.0  93  22.0  54  39  --
AL 277  252  91.0 25  9.0 --  1  24
TI 3  --  --  3  100  3  --  --
Results in n, except when pointed out. IC: inhaled corticoids; NC: nasal topic corticoids; LABA: long acting 2 agonist; AH: oral
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* p < 0.001.
Although  the  overall  prescribing  for  children  aged  <2
ears  was  lower  than  in  older  children,  off-label  use  was
elatively  much  more  frequent.  Up  to  73.5%  of  prescriptions
n  this  age  group  were  off-label  compared  with  27.7%  in
he  oldest  age  group  (Table  4).  This  difference  was  statisti-
ally  significant  (p  <0.001).  Note  that,  with  one  exception,
ll  children  aged  <2  years  received  at  least  one  off-label
rescription.
iscussion
his  study  provides  detailed  and  original  information  about
ational  off-label  prescribing  for  the  allergic  diseases
sthma,  allergic  rhinitis,  and  atopic  eczema  in  the  paedi-
tric  population.
We  found  that,  in  pre-school  children,  the  use  of  drugs
or  these  conditions  in  moderate  to  severe  forms  is  frequent
34.5%),  particularly  in  children  aged  <2  years,  with  more
han  73%  of  prescriptions  made  for  this  group.  This  is  proba-
ly  due  to  the  absence  of  data  on  the  safety  and  efficacy  of
rugs  at  this  age  group,  owing  to  the  lack  of  clinical  trials.1--4
The  lack  of  clinical  research  in  the  paediatric  popula-
ion,  mainly  in  infants,  results  from  a  combination  of  factors
hat  can  contribute  to  this  age  group  being  the  last  to
enefit  from  medical  progress.2,13 Pharmaceutical  compa-
ies,  which  can  never  promote  or  recommend  off-label  use
f  their  drugs,  apparently  view  the  approval  of  drugs  in  chil-
ren  as  a  market  that  would  bring  small  financial  benefit,
ith  only  a  few  drugs  representing  a  large  enough  economic
nterest.  As  such,  it  is  not  surprising  that  the  drugs  that  have
een  adequately  studied  in  children  are  anti-infectious  vac-
ines  and  some  antibiotics.  Specific  medical  techniques  and
ppropriate  equipment  are  also  necessary  for  clinical  inves-
igation  in  the  paediatric  population;  technical  procedures
hat  seem  simple  in  adults,  such  as  drawing  blood,  among
ther  minimally  invasive  interventions,  can  be  difficult  toPlease  cite  this  article  in  press  as:  Morais-Almeida  M,  Cabral  A
children.  Allergol  Immunopathol  (Madr).  2013.  http://dx.doi.o
xecute  or  even  authorise  in  children.  Lastly,  the  ethical
mplications  in  children  are  more  complex,  with  potential
isks  associated  with  the  intervention,  and  significantly  hin-
er  clinical  trials  in  this  population.14
a
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jThe  clinical  investigation  of  drugs  in  the  paediatric
opulation  is  regulated  by  international  standards  (ICH  E11),
ncluding  European  (EC  no.  1902/2006),  which  set  out  spe-
ific  requirements  for  the  protection  of  children  in  clinical
rials.15,16 However,  the  current  EMA  regulations  encourage
esearch  and  development  of  drugs  in  the  paediatric  popu-
ation  to  improve  the  available  information  on  these  drugs,
y  assigning  benefits  to  the  pharmaceutical  industry  like
xtending  the  period  of  patent  exclusivity.17,18
Nonetheless,  most  drugs  available  on  the  market  are  not
pecifically  tested  in  children,  particularly  younger  children.
n  Portugal,  Infarmed  has  specialised  committees,  namely
he  Committee  for  the  Evaluation  of  Medicinal  Products,
hich  is  responsible  for  issuing  opinions  on  the  quality,
afety,  and  efficacy  of  drugs  within  their  marketing  authori-
ations  (AIM).  They  have  the  responsibility  for  reviewing  and
pproving  the  Summaries  of  Product  Characteristics  (RCM).
owever,  the  use  of  drugs  outside  their  authorised  RCM  is
ot  the  concern  of  authorities  and  is  the  sole  responsibility
f  the  prescriber.19
This  study  showed  a  great  number  of  off-label
rescriptions,  although  it  can  be  overestimated  related  with
he  severity  of  the  clinical  manifestations  of  the  included
hildren;  these  values  must  be  interpreted  with  caution,
owever,  as  they  may  suggest  inadequate  or  inappropriate
se.  Off-label  prescribing  is  not  necessarily  incorrect6 and  is
ontemplated  in  several  therapeutic  guidelines  that  include
aediatric  populations,  but  remarkably  with  no  indication
hat  some  of  the  drugs  are  being  recommended  for  unli-
ensed  and  off-label  use.20 In  fact,  indications  for  drug  use  in
herapeutic  guidelines  do  not  clinically  or  legally  authorise
heir  use,  even  if  the  guidelines  support  it.
Off-label  prescribing  is  frequently  necessary,  but  should
e  evaluated  according  to  clinical  indications,  therapeutic
lternatives,  and  risk-benefit  considerations,  and  off-label
se  implies  obtaining  informed  consent  from  the  patient  or
uardian.  However,  if  off-label  use  of  drugs  does  not  requireJ.  Off-label  prescribing  for  allergic  diseases  in  pre-school
rg/10.1016/j.aller.2013.02.011
 signed  informed  consent  by  the  patient  or  his  or  her  legal
epresentative,  is  oral  consent  enough?  In  the  prescriptions
tudied,  off-label  drug  use  was  systematically  indicated  and
ustified  to  the  parents  or  caretakers  as  well  as  the  clinical
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necessity  for  the  drug’s  use,  which  was  invariably  authorised
after  the  requested  clarifications,  increasing  the  compli-
ance  to  the  indicated  treatments.  This  type  of  information
is  very  important  for  patient  and  caregiver  adherence,  but
it  is  often  omitted.  A  survey  conducted  in  the  UK  found
that  most  paediatricians  did  not  obtain  informed  consent,
or  inform  the  children’s  parents  that  the  drug’s  use  was
off-label,  which  could  indicate  poor  medical  practice.21
From  the  prescriptions  studies,  we  note  the  very  frequent
off-label  use  of  a  very  safe  topical  nasal  corticosteroid,
mometasone.  The  reason  for  off-label  use  was  entirely  due
to  its  use  outside  the  authorised  age  group,  as  it  is  only
approved  for  children  aged  ≥6  years.  This  imposition  is  made
by  EMA,  whereas  the  U.S.  Food  and  Drug  Administration
(FDA)  already  allows  the  use  of  this  drug  in  younger  children,
i.e.  those  aged  >2  years.22 Despite  the  discrepancy  in  per-
missions,  the  fact  that  the  FDA,  which  is  responsible  for  the
regulation  of  drugs  in  the  United  States,  has  already  autho-
rised  broader  use  of  this  drug  offers  additional  security  for
prescribing  it  off-label  in  Europe.  If  the  authorisations  were
identical,  off-label  use  of  mometasone  would  be  only  4.3%.
The  same  can  be  said  of  the  use  of  some  antihistamines,
in  particular  levocetirizine,  whose  off-label  use  was
approximately  25%,  and  almost  entirely  due  to  its  use  in
children  aged  under  the  authorised  age.  As  of  2009,  the  FDA
approved  prescribing  this  drug  for  children  and  infants  from
six  months  of  age22 after  publication  of  long-term  trials
that  demonstrated  its  safety  and  efficacy  in  this  paediatric
population.23 In  our  pharmaceutical  market,  levocetirizine
is  still  only  approved  for  children  aged  >2  years.11 As  in  the
above-mentioned  case,  if  the  indications  were  the  same
on  both  continents,  off-label  prescribing  of  this  drug  would
have  been  irrelevant.
Regarding  topical  immunomodulators,  pimecrolimus  was
prescribed  for  only  three  cases  of  atopic  eczema,  but  always
off-label  for  age,  despite  its  use  being  justified  by  clini-
cal  severity.  This  pathology  appears  in  over  60%  of  patients
before  the  age  of  12  months;24 however,  these  drugs  are
only  approved  for  children  aged  >2  years  by  both  the  FDA
and  EMA.11,22,25 This  limitation  was  imposed  because  there
are  no  current  studies  of  long-term  safety  that  are  deemed
sufficient  for  approval  in  younger  children.  The  concerns  of
the  regulatory  authorities  are  based  on  the  theoretical  risk
of  systemic  immunosuppression  derived  from  the  use  of  oral
calcineurin  inhibitors  such  as  pimecrolimus  or  tacrolimus  in
transplant  recipients,  and  the  existence  of  rare  instances  of
malignancy  associated  with  their  use.26 However,  pharma-
cokinetic  data  obtained  from  clinical  trials  in  children  aged
<2  years  did  not  suggest  concentrations  high  enough  to  cause
systemic  immunosuppression,  unlike  oral  administration, or
demonstrate  a  correlation  between  systemic  concentrations
and  percentage  body  surface  area  treated  or  the  duration  of
treatment.27 Likewise,  there  was  no  interference  with  the
development  of  normal  immune  responses  to  vaccinations.28
Besides  demonstrating  extreme  efficacy,  these  trials  demon-
strate  safety  data  for  IT  use  in  atopic  eczema,  but  more
extensive  surveillance  is  needed  to  determine  long-term
safety.  Nonetheless,  since  its  introduction  on  the  market  inPlease  cite  this  article  in  press  as:  Morais-Almeida  M,  Cabral  A
children.  Allergol  Immunopathol  (Madr).  2013.  http://dx.doi.o
2001,  no  definite  causal  relationship  between  the  use  of  IT
and  malignancy  has  been  established.26
In  this  study,  we  confirmed  that  the  off-label  use  of  anti-
allergic  drugs  in  pre-school-aged  children  for  the  treatment
C
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f  moderate  to  severe  allergic  diseases  is  high.  With  few
tudies  of  long-term  safety,  the  implications  inherent  in  this
ype  of  use  become  evident.  The  Paediatric  Committee  of
he  EMA  has  issued  a  list  of  drugs  currently  administered
o  children  for  which  information  on  pharmacokinetics,
fficacy,  and  safety  are  urgently  needed;  fluticasone  and
ontelukast,  among  others,  were  included.29 The  standard
ethod  consists  of  performing  randomised  controlled  tri-
ls,  which  are  limited  by  methodological  difficulties,  hence
he  need  to  develop  sufficiently  extensive  post-marketing
bservational  studies  in  order  to  obtain  sufficient  data  to
valuate  the  safety  and  efficacy  of  drugs  used  in  paediatric
opulations.
In  some  emerging  diseases  in  our  area  of  expertise  the
ajority  of  drugs  available  that  provide  the  best  results  are
sed  off-label  regardless  of  age.30
The  presence  of  complete  and  updated  records  with
etailed  information  on  the  drugs  used,  dosages,  routes
f  administration,  and  adverse  effects  are  important  in
btaining  reliable  data  essential  for  further  evaluation  of  the
afety  and  efficacy  of  drugs  in  which  more  complex  studies
n  children  are  not  feasible  for  practical  and/or  ethical
easons.  As  with  other  populations  with  unique  character-
stics,  such  as  pregnant  women  and  the  elderly,  publication
nd  distribution  of  this  information  by  the  scientific  com-
unity  is  critical  for  the  acquisition  of  new  safety  data,
llowing  the  approval  of  new  dosages,  clinical  indications,
nd/or  prescribing  for  younger  children,  reducing  off-label
rug  use  that,  although  often  appropriate,  is  not  without
isks.
Finally,  this  study  should  increase  clinicians’  awareness
f  prescribing  drugs  off-label  such  that  they  are  available  at
ny  time  to  discuss  use  of  the  drugs  with  patients  and  their
amilies,  as  well  as  provide  the  motives  that  justify  their
se,  valuing  benefits  versus  risks,  increasing  compliance  and
ontributing  to  achieve  better  outcomes.
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